{
 "name": "智新生技",
 "slug": "tw-7832",
 "aliases": [
  "智新生技股份有限公司",
  "Intelligene",
  "7832"
 ],
 "ticker": "7832",
 "industry": "生技醫療業",
 "website": "https://www.intelli-gene.com",
 "summary": "智新生技（7832）是興櫃的生技醫療類股公司，2023 年成立，2025 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "智新生技股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "Intelligene",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2025-05-08",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2023-06-02",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "黃先龍",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "宋佩怡",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 580000000,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "勤業眾信聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "https://www.intelli-gene.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：IG-001（siRNA核酸藥物）",
   "value": "新冠肺炎｜臨床前試驗進行中｜全球專屬授權",
   "unit": "",
   "as_of": "2026-07-16",
   "source": "https://www.intelli-gene.com/simg_thumbs/meetingdownload/49eaa45dc9516f17.pdf",
   "note": "簡報頁13、18、23；全球為權利範圍，不宣稱已於全球展開人體試驗。"
  },
  {
   "claim": "管線：IG-002（siRNA核酸藥物）",
   "value": "廣效型流行性感冒｜臨床前試驗進行中｜全球專屬授權",
   "unit": "",
   "as_of": "2026-07-16",
   "source": "https://www.intelli-gene.com/simg_thumbs/meetingdownload/49eaa45dc9516f17.pdf",
   "note": "簡報頁13、18、23；全球為權利範圍，不宣稱已於全球展開人體試驗。"
  },
  {
   "claim": "簽約金：IG-001",
   "value": 115000,
   "unit": "澳幣",
   "as_of": "2026-08-11",
   "source": "https://www.intelli-gene.com/simg_thumbs/reportdownload/867d901360c77609.pdf",
   "note": "財報頁32稱「首次授權金」；原幣AUD仟元換為澳幣元。IG-001對應肺部感染疾病新藥、IG-002對應廣泛型流感新藥，代號與Gene授權關係另由2026-05-29年報頁55確認。此為授權引進之應付首次授權金，不是智新已收金額。as_of為該期財報MOPS正式公告日：發言日期115/08/11 16:17:32，7832、序號1，主旨「公告本公司提報董事會115年第二季合併財務報告」，查詢頁https://mops.twse.com.tw/mops/#/web/t05st01（代號7832、115年、8月11日）。公告期別及資產917,838千元／負債55,209千元與本PDF一致，未把董事會日或PDF上傳日逕當發布日。"
  },
  {
   "claim": "簽約金：IG-002",
   "value": 100000,
   "unit": "澳幣",
   "as_of": "2026-08-11",
   "source": "https://www.intelli-gene.com/simg_thumbs/reportdownload/867d901360c77609.pdf",
   "note": "財報頁32稱「首次授權金」；原幣AUD仟元換為澳幣元。IG-001對應肺部感染疾病新藥、IG-002對應廣泛型流感新藥，代號與Gene授權關係另由2026-05-29年報頁55確認。此為授權引進之應付首次授權金，不是智新已收金額。as_of為該期財報MOPS正式公告日：發言日期115/08/11 16:17:32，7832、序號1，主旨「公告本公司提報董事會115年第二季合併財務報告」，查詢頁https://mops.twse.com.tw/mops/#/web/t05st01（代號7832、115年、8月11日）。公告期別及資產917,838千元／負債55,209千元與本PDF一致，未把董事會日或PDF上傳日逕當發布日。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-7832.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}